Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst

Iveric Bio (ISEE) PT Raised to $21 at Wedbush

September 10, 2021 7:41 AM EDT

Wedbush analyst David Nierengarten raised the price target on Iveric Bio (NASDAQ: ISEE) to $21.00 (from $16.00) while maintaining an Outperform rating.

"In our opinion the Phase 3 results announced by APLS (Neutral, Laura Chico) represent a best-case scenario for ISEE shares," the analyst commented.

... More

Iveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'

September 10, 2021 6:48 AM EDT

Cowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.

The analyst commented, "The APLS results could not... More

Iveric Bio (ISEE) PT Raised to $18 at Credit Suisse

September 10, 2021 6:09 AM EDT

Credit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $18.00 (from $15.00) while maintaining a Outperform rating.... More

Stifel Starts Iveric Bio (ISEE) at Buy

September 10, 2021 1:59 AM EDT

Stifel analyst Annabel Samimy initiates coverage on Iveric Bio (NASDAQ: ISEE) with a Buy rating and a price target of $22.00.

The analyst comments "We are initiating coverage of IVERIC bio (ISEE) with a Buy rating and a 12-month target price of... More

After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)

September 9, 2021 5:52 PM EDT

After-Hours Stock Movers:

IVERIC bio (NASDAQ: ISEE) 41.4% HIGHER; gains following data from Apellis

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 30.8% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively,... More

UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)

September 9, 2021 4:14 PM EDT

(Updated - September 9, 2021 4:22 PM EDT)

IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)

Shares Up 17%

Update:

Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More